Astrana Health, Inc. (NASDAQ:ASTH)
| Market Cap | 1.84B+20.9% |
| Revenue (ttm) | 3.84B+58.9% |
| Net Income | 40.55M+60.5% |
| EPS | 0.82+57.2% |
| Shares Out | 49.58M |
| PE Ratio | 44.88 |
| Forward PE | 18.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 664,493 |
| Open | 36.65 |
| Previous Close | 37.00 |
| Day's Range | 36.65 - 37.66 |
| 52-Week Range | 18.08 - 51.60 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 52.00(+40.01%) |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ASTH
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985. This company delivers medical services throughout the United States, operating with a physician-centered approach powered by advanced technology. Its operations are structured across three distinct divisions: Care Partners, Care Delivery, and Care Enablement. Astrana Health utilizes its exclusive platform for population health management and healthcare delivery to implement an integrated, value-based care model. This strategic approach empowers the healthcare providers within its network to offer high-quality care to their patients. The organization provides extensive care coordination services to a broad spectrum of stakeholders, including patients, their families, primary care physicians, specialists, acute care hospitals, other inpatient facilities, physician groups, and health plans. Its robust physician network encompasses primary care doctors, specialized practitioners, advanced practice providers (extenders), and hospital-based physicians. Astrana Health serves a diverse patient base, primarily those with insurance coverage—such as private plans, Medicare, Medicaid, and HMOs—but also extends care to uninsured individuals.
$ASTH stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ASTH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ASTH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ASTH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ASTH Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Medicare | $593.88M | 61.07% |
| Medicaid | $265.62M | 27.31% |
| Commercial | $87.19M | 8.97% |
| Other third parties | $25.84M | 2.66% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ASTH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ASTH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ASTH
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $54.00M |
| IWMiShares Russell 2000 ETF | $43.93M |
| VBVanguard Morningstar Small-Cap ETF | $39.04M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $22.38M |
| VXFVanguard Extended Market ETF | $18.76M |
| IWOiShares Russell 2000 Growth ETF | $15.81M |
Estimated from each fund’s disclosed top holdings × AUM
ASTH Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ASTH’s recent data — informational, not investment advice
